Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience (DARE)
:DARE
DARE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.67 - $10.72
Previous CloseN/A
Volume4.87K
Average Volume (3M)25.91K
Market Cap
$25.07M
Enterprise Value$22.31M
Total Cash (Recent Filing)$6.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 31, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding8,700,389
10 Day Avg. Volume20,737
30 Day Avg. Volume25,909
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.39
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.06
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$12.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Daré Bioscience News
PremiumCompany Announcements
Daré Bioscience to Present at BIO CEO Conference
PremiumCompany Announcements
Daré Bioscience Announces New Corporate Presentation
PremiumCompany Announcements
Daré Bioscience Advances Sildenafil Cream to Phase 3 Study
---
Bulls Say, Bears Say
Bulls Say
Funding And GrantsThe recent grant from the Gates foundation injected ~$11M into the Ovaprene program, allowing DARE to expand enrollment sites.
Product DevelopmentOvaprene is considered an exciting opportunity as it could be a blockbuster contraceptive device given the lack of convenient non-hormonal products on the market.
Strategic PartnershipsBayer may exercise its commercial option for Ovaprene after Phase 3 readout, potentially bringing in an additional $20M.
Bears Say
Financial ConstraintsRisks include financial because the company has capital needs greater than the company's current cash balance, and it is likely going to need to raise additional capital.
Regulatory And Development ChallengesSildenafil cream is intriguing but still needs FDA alignment, and there is uncertainty around the regulatory pathway.
Revenue Performance3Q24 revenue came in below the estimate of $3.1M and the Street consensus of $1M.
---
Ownership Overview
12.23%
Insiders
4.30% Mutual Funds
1.74% Other Institutional Investors
78.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DARE FAQ
What was Daré Bioscience’s price range in the past 12 months?
Daré Bioscience lowest stock price was $2.67 and its highest was $10.72 in the past 12 months.
What is Daré Bioscience’s market cap?
Daré Bioscience’s market cap is $25.07M.
When is Daré Bioscience’s upcoming earnings report date?
Daré Bioscience’s upcoming earnings report date is Mar 31, 2025 which is in 4 days.
How were Daré Bioscience’s earnings last quarter?
Daré Bioscience released its earnings results on Nov 14, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.685 by $0.135.
Is Daré Bioscience overvalued?
According to Wall Street analysts Daré Bioscience’s price is currently Undervalued.
Does Daré Bioscience pay dividends?
Daré Bioscience does not currently pay dividends.
What is Daré Bioscience’s EPS estimate?
Daré Bioscience’s EPS estimate is -0.53.
How many shares outstanding does Daré Bioscience have?
Daré Bioscience has 8,700,389 shares outstanding.
What happened to Daré Bioscience’s price movement after its last earnings report?
Daré Bioscience reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.685. Following the earnings report the stock price went down -9.831%.
Which hedge fund is a major shareholder of Daré Bioscience?
Currently, no hedge funds are holding shares in DARE
---
Company Description
Daré Bioscience
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
---
DARE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including substantial nondilutive funding, progress in product pipeline and clinical trials, and steady market progress for XACIATO. However, challenges remain with decreased R&D spending, operational hurdles for Sildefanil Cream, and overall financial losses.Read More>---
DARE Stock 12 Month Forecast
Average Price Target
$12.00
▲(316.67% Upside)
Technical Analysis
Best Analysts Covering DARE
1 Year
1 Year Success Rate
0/20 ratings generated profit
1 Year Average Return
-45.32%
reiterated a buy rating 3 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -45.32% per trade.
---